Prospective comparison of PSA kinetics following two different prostate cancer brachytherapy planning methods: Preoperative and real-time intraoperative dosimetry planning

Haim Matzkin, Juza Chen, Amira Stenger, Rubi Agai, Nicola J. Mabjeesh*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Objectives: Preoperative planning (PP) and intraoperative planning (IoP) are established 125 I-brachytherapy techniques for the treatment of localized prostate cancer. We prospectively compared the effects of each method on reducing PSA levels. Materials and methods: One hundred eighty patients treated with brachytherapy as monotherapy without neoadjuvant androgen deprivation therapy or external beam radiation using PP (75) or IoP (105) methodologies and with ≥5 years of follow-up were included in the study. CT-based dosimetry was calculated 1 month postoperatively. PSA was obtained every 3 months for the first year and semiannually thereafter. Available PSA and dosimetric data from both groups were analyzed and compared. Results: At 5 years after brachytherapy, the probability of having a nadir PSA value < 0.5 ng/ml was 90% in the IoP group compared with 60% in the PP group (P < 0.0001). The rate of PSA decline was 3-fold faster in the IoP group than in the PP group. Dosimetry results highly favored the IoP method: mean V100 (%) and D90 (Gy) were 95 and 180 vs. 60 and 81 (P < 0.001), respectively Conclusions: Our initial finding of highly superior postimplant CT dosimetry calculations of the IoP method are now substantiated by the biochemical favorable results (PSA kinetics) of this method.

Original languageEnglish
Pages (from-to)379-385
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume30
Issue number4
DOIs
StatePublished - Jul 2012

Keywords

  • Brachytherapy
  • Implant technique
  • PSA kinetics
  • Prostate cancer

Fingerprint

Dive into the research topics of 'Prospective comparison of PSA kinetics following two different prostate cancer brachytherapy planning methods: Preoperative and real-time intraoperative dosimetry planning'. Together they form a unique fingerprint.

Cite this